However, the efficacy of “immune checkpoint” blocking antibodies targeting PD-1/PD-L1 axis depends on tumor expression of HLA-I molecules and the limited clinical efficacy of immunotherapy could be partially explained by the tumor HLA-I loss [4–8, 17] . The gene discussed is CD274; the disease is neoplasm.